Cryo Cell International Inc (NYSE: CCEL)

Cryo-Cell International, Inc. is organized in three reportable segments: cellular processing and cryogenic storage for family use, the manufacture of PrepaCyte® CB Processing System units, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company provides services for the collection, processing, testing, and long-term storage of umbilical cord blood and tissue stem cells. It operates from its headquarters in Oldsmar, Florida, and utilizes a technologically advanced facility in Durham, North Carolina for specimen storage.

The company generates revenue through processing and storage fees for umbilical cord blood and tissue specimens, annual storage fees, and prepaid storage plans. It also earns income from the manufacture and sale of PrepaCyte® CB Processing System units used to process umbilical cord blood stem cells. Additionally, revenue is derived from public cord blood banking activities, including the distribution of units through the National Marrow Donor Program, and from third-party biorepository services such as ExtraVault.

The company operates through the following segments:

• Cellular processing and cryogenic storage for family use: This segment focuses on the collection, processing, testing, and cryopreservation of umbilical cord blood and tissue stem cells for individual family use. It offers services including the collection kit, processing, testing, and first-year storage, followed by annual storage fees or prepaid plans. The segment utilizes the PrepaCyte® CB Processing System for stem cell recovery and red blood cell depletion.

• Manufacture of PrepaCyte® CB Processing System units: This segment involves the production of the PrepaCyte® CB Processing System, a medical device used to process umbilical cord blood stem cells prior to banking. The system is a 510(k) cleared Class II device composed of three integrally attached processing and storage containers with separation media. It is designed to maximize recovery of healthy stem cells and provide superior red blood cell depletion compared to other methods.

• Cellular processing and cryogenic storage of umbilical cord blood stem cells for public use: This segment handles the processing and storage of donated umbilical cord blood units for public use through the National Marrow Donor Program. The company acquired substantially all assets of Cord:Use Cord Blood Bank, Inc. in June 2018 to establish this public inventory. The units are listed on the NMDP registry and distributed to transplant centers worldwide, with the company receiving cost recovery for units distributed.

Cryo-Cell International, Inc. holds a leadership position in the private cord blood banking industry as the world’s first private cord blood bank, having separated and stored stem cells since 1992. The company differentiates itself through its cGMP- and cGTP-compliant facility, AABB and FACT accreditations, and a 100% viability rate of specimens upon thaw since inception. It competes against approximately 25 other national private cord blood banks and believes its value-based pricing, superior customer service, and technical expertise provide a competitive advantage.

The company serves expectant parents seeking to preserve their newborn’s umbilical cord blood and tissue stem cells for potential future family use. It also serves patients in need of stem cell transplants through its public cord blood banking program, with units distributed via the National Marrow Donor Program to transplant centers in the United States and worldwide. Additionally, the company provides biorepository services to pharmaceutical companies and healthcare institutions through its ExtraVault facility.